Oragenics reported early progress in its Phase IIa trial of ONP-002 for mild traumatic brain injury, with two patients enrolled and eight study drug doses administered. The update is incremental and operational rather than outcome-driven, so it is unlikely to materially move shares absent efficacy or safety data.
Oragenics reported early progress in its Phase IIa trial of ONP-002 for mild traumatic brain injury, with two patients enrolled and eight study drug doses administered. The update is incremental and operational rather than outcome-driven, so it is unlikely to materially move shares absent efficacy or safety data.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
neutral
Sentiment Score
0.15
Ticker Sentiment
